Concepedia

Isabel Schemainda

IS

Statistics

Publications

5

Citations

886

H-Index

5

Active since

2002

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Isabel Schemainda is an author at Memorial Sloan Kettering Cancer Center specializing in pharmacology, oncology, and life sciences.

Publications per year

2002–2006

5

Publications

5

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

Max Hasmann, Isabel Schemainda · PubMed · 2003 · 635 citations

Life Sciences, Biochemistry, Pharmacology +17

Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy

Manickam Muruganandham, Alan Alfieri, Cornelia Matei et al. · Clinical Cancer Research · 2005 · 90 citations

Life Sciences, Oncology, Pharmacology +17

WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.

Katja Wosikowski, Karin Mattern, Isabel Schemainda et al. · PubMed · 2002 · 89 citations

Life Sciences, Oncology, Pharmacology +17

Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.

A Pogrebniak, Isabel Schemainda, K Azzam et al. · PubMed · 2006 · 61 citations

Medicine, Oncology, Pharmacology +14

Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.

A Pogrebniak, Isabel Schemainda, R. Pelka‐Fleischer et al. · PubMed · 2003 · 11 citations

Life Sciences, Oncology, Pharmacology +16

1–5 of 5